Table of Contents
Volume 2014 (2014), Article ID 205215, 12 pages
Research Article

Impact of BMI and Gender on Outcomes in DLBCL Patients Treated with R-CHOP: A Pooled Study from the LYSA

1Service d’Hématologie Clinique, Centre Hospitalier Lyon-Sud, Hospices Civiles de Lyon, 69310 Pierre Bénite, France
2Service d’Hématologie, CHU de Nice, 06000 Nice, France
3Service d’Hématologie Clinique, CHU de Reims, 51100 Reims, France
4Service d’Hématologie, General Hospital St. Jan, B8000 Brugge, Belgium
5Service d’Onco-hématologie, Hôpital Saint Louis, 1700 La Rochelle, France
6Service d’Hématologie Clinique, Institut Jules Bordet, 1000 Bruxelles, Belgium
7Service d’Hématologie, Centre Hospitalier de Mulhouse Hasenrein, 68100 Mulhouse, France
8Service d’Hématologie, Centre Hospitalier Necker, 75015 Paris, France
9Institut Régional du Cancer, 34070 Montpellier, France

Received 21 September 2013; Accepted 17 November 2013; Published 16 January 2014

Academic Editor: Umberto Vitolo

Copyright © 2014 Clémentine Sarkozy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


In diffuse large B-cell lymphoma (DLBCL), the age-adjusted International Prognostic Index (aaIPI) score is currently used to predict patient outcomes and to choose the best therapeutic treatment. Body mass index (BMI) and gender are occasionally sited as prognostic factors; however, their value has never been studied in a large series of patients included in prospective clinical trials in the rituximab era. To assess the impact of BMI and gender on OS and PFS independently of the aaIPI score, we pooled 985 patients that were prospectively included in GELA studies and uniformly treated with R-CHOP. Univariate analysis indicated that high aaIPI and male gender were associated with a worse PFS, whereas high (>25) or low (<18.5) BMI scores were not. High aaIPI score was the only factor predictive for OS. In a multivariate analysis, including aaIPI score, gender, BMI, and interaction between BMI and gender, aaIPI remained the strongest predictive factor, and BMI < 18.5 was significantly associated with a worse OS but not PFS. In conclusion, in the rituximab era, the aaIPI score remains the major predictor of outcome in DLBCL patients; however, male gender and low BMI seem to impact outcome.